Dollars for Donuts: Inside the Key Elements of PhRMA's Health Reform Deal
This article was originally published in RPM Report
Executive Summary
The key part of PhRMA's deal with the Finance Committee is a double win for industry: assuring that closing the donut hole will be part of reform, and that PhRMA will get credit for a big part of the savings.
You may also be interested in...
MedPAC To The Rescue? How US Policy Advisors Could Save The Drug Industry
The Congressionally-chartered Medicare Payment Advisory Commission is preparing a formal endorsement of a plan to overhaul Part D. It will come just in time to help move stalled legislation – and that legislation may be the best chance the drug industry has to fend off draconian pricing measures in 2021.
Co-pay Coupons and the ACA: Despite HHS Ruling, Insurers Still Hold The Cards
The Obama Administration OKs the use of co-pay cards for brand prescription drugs in the ACA-created insurance exchanges. One prominent Republican intends to investigate the decision. But insurers and PBMs can decide whether or not to accept them—a fact being lost in the debate.
"Dollars for Donuts" Deal Revisited: What Pharma Got
A Kaiser Family Foundation report on the impact of the Medicare Part D donut hole reads like an artifact of history. But it helps quantify the benefit to brand name industry from closing the donut hole in the context of health care reform.